University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.

Natalie GalaninaSonali M SmithChuanhong LiaoAdam PetrichBernadette LibaoRonald GartenhausJason R WestinKenneth S CohenJames A KnostWalter M StadlerAustin DoyleTheodore KarrisonLeo I GordonAndrew M Evens

Published in: British journal of haematology (2017)

Keyphrases

phase ii
open label
diffuse large b cell lymphoma
phase iii
clinical trial
placebo controlled
double blind
acute lymphoblastic leukemia
acute myeloid leukemia
study protocol
multiple myeloma
hodgkin lymphoma
randomized controlled trial